PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsOverweight
MeSH D050177 - overweight
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D044343:Overnutrition
0 Companies
0 Drugs
Success rate
D001835:Body weight
0 Companies
0 Drugs
Success rate
D050177: 
Overweight
$
Success rate
D009765:Obesity
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Novo NordiskLiraglutide Saxenda  2015-03-23   
Semaglutide Wegovy  2022-01-06   
Orexigen TherapeuticsBupropion, Naltrexone Mysimba  2015-03-26   
Clinical Trials
Historical Success Rate
Phase 1
50%
7/14
Phase 2
36%
14/39
Phase 3
50%
14/28
Approved: 4Overall Success rate: 9%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Novo Nordisk
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use